Citron Research Out Negative on J2 Global (JCOM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to Citron Research Out Negative on J2 Global (JCOM)
March 11, 2016 9:37 AM EST
Guggenheim affirms Valeant Pharma (NYSE: VRX) with a Buy rating and $145 price target following recent dermatology prescription performance checks.
Analyst Louise Chen noted the following on Friday:
VRX dermatology Rxs reached ~80% of their levels prior to any disruption from Philidor (October '15) levels up from ~75% last week. TRx's for derm...
More
March 11, 2016 6:06 AM EST
j2 Global, Inc. (Nasdaq: JCOM). j2 is aware of a report issued yesterday that we believe is both factually incorrect and wrongly... More
March 10, 2016 2:06 PM EST
(Updated - March 10, 2016 3:04 PM EST)
Some traders are suggesting Citron Research was recommending a short on J2 Global (NASDAQ: JCOM) 10 years ago when it was Stocklemon. It is unclear if this is the case. Shares are hitting the lows of the session down 20%... More
March 10, 2016 11:48 AM EST
J2 Global (NASDAQ: JCOM) Shares Dip
...
More
